CD38 and acute myeloid leukemia: Pilot Study of the Efficacy and Safety of CD38 Targeted Chimeric Antigen Receptor Enginerred T-Cells in the Treatment of CD38 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)